A Tisento Therapeutics Inc. patent describes new soluble guanylate cyclase (sGC) activators reported to be useful for the treatment of Alzheimer’s and Parkinson’s diseases, vascular dementia, ischemic stroke, Leigh syndrome, Pearson syndrome, creatine deficiency syndrome and Alpers syndrome, among others.